IBA Secures Duke Health Deal for Two Proteus®ONE Proton Therapy Systems
LOUVAIN-LA-NEUVE, Belgium, June 8, 2026 IBA (Ion Beam Applications), a global leader in particle accelerator technology and proton therapy...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LOUVAIN-LA-NEUVE, Belgium, June 8, 2026 IBA (Ion Beam Applications), a global leader in particle accelerator technology and proton therapy...
Louvain-la-Neuve, Belgium, May 20, 2026 IBA announced the launch of Rhodotron® LITE, a new low-power X-ray accelerator designed to...
